vs
Side-by-side financial comparison of Lanvin Group Holdings Ltd (LANV) and Mirum Pharmaceuticals, Inc. (MIRM). Click either name above to swap in a different company.
Mirum Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($148.9M vs $144.1M, roughly 1.0× Lanvin Group Holdings Ltd).
Lanvin is a French luxury fashion house founded in 1889 by Jeanne Lanvin in Paris. It is the oldest French fashion house still in operation. Since 2018, it has been a subsidiary of Shanghai-based Lanvin Group. Lanvin Group includes Lanvin, Sergio Rossi, Wolford, St. John Knits, and Caruso.
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
LANV vs MIRM — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $144.1M | $148.9M |
| Net Profit | — | $-5.7M |
| Gross Margin | 53.9% | — |
| Operating Margin | -60.5% | -3.1% |
| Net Margin | — | -3.8% |
| Revenue YoY | — | 49.8% |
| Net Profit YoY | — | 75.9% |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $148.9M | ||
| Q3 25 | — | $133.0M | ||
| Q2 25 | $144.1M | $127.8M | ||
| Q1 25 | — | $111.6M | ||
| Q4 24 | — | $99.4M | ||
| Q3 24 | — | $90.4M | ||
| Q2 24 | $184.7M | $77.9M | ||
| Q1 24 | — | $69.2M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $-5.9M | ||
| Q1 25 | — | $-14.7M | ||
| Q4 24 | — | $-23.8M | ||
| Q3 24 | — | $-14.2M | ||
| Q2 24 | — | $-24.6M | ||
| Q1 24 | — | $-25.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 53.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 57.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -3.1% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | -60.5% | -3.9% | ||
| Q1 25 | — | -13.6% | ||
| Q4 24 | — | -24.4% | ||
| Q3 24 | — | -14.0% | ||
| Q2 24 | -35.0% | -31.1% | ||
| Q1 24 | — | -38.2% |
| Q4 25 | — | -3.8% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | -4.6% | ||
| Q1 25 | — | -13.2% | ||
| Q4 24 | — | -23.9% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | — | -31.6% | ||
| Q1 24 | — | -36.5% |
| Q4 25 | — | $-0.10 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.30 | ||
| Q4 24 | — | $-0.49 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $-0.52 | ||
| Q1 24 | — | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.1M | $383.3M |
| Total DebtLower is stronger | $290.3M | — |
| Stockholders' EquityBook value | $-116.4M | $314.7M |
| Total Assets | $632.1M | $842.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $383.3M | ||
| Q3 25 | — | $375.5M | ||
| Q2 25 | $32.1M | $304.6M | ||
| Q1 25 | — | $277.7M | ||
| Q4 24 | — | $280.3M | ||
| Q3 24 | — | $284.4M | ||
| Q2 24 | $19.3M | $278.4M | ||
| Q1 24 | — | $302.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $290.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $136.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $314.7M | ||
| Q3 25 | — | $292.0M | ||
| Q2 25 | $-116.4M | $255.2M | ||
| Q1 25 | — | $233.3M | ||
| Q4 24 | — | $225.6M | ||
| Q3 24 | — | $232.0M | ||
| Q2 24 | $100.1M | $229.0M | ||
| Q1 24 | — | $234.6M |
| Q4 25 | — | $842.8M | ||
| Q3 25 | — | $785.1M | ||
| Q2 25 | $632.1M | $725.8M | ||
| Q1 25 | — | $690.2M | ||
| Q4 24 | — | $670.8M | ||
| Q3 24 | — | $667.9M | ||
| Q2 24 | $731.8M | $660.8M | ||
| Q1 24 | — | $652.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-75.1K | $6.1M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 3.7% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $54.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $39.7M | ||
| Q2 25 | $-75.1K | $12.0M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-36.2K | $-3.8M | ||
| Q1 24 | — | $15.2M |
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $39.5M | ||
| Q2 25 | — | $11.9M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $3.8M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $15.2M |
| Q4 25 | — | 3.7% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | 4.2% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | — | 22.0% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 13.66× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LANV
Segment breakdown not available.
MIRM
| Livmarli | $106.4M | 71% |
| Bile Acid Medicines | $42.5M | 29% |
